Mutual Funds Sahi Hai!
To avail the service, you will be redirected to loans.geojitcredits.com
The certification for the Patalganga site follows ANVISA’s review of the inspection report of U.S. FDA, along with other documents submitted by the company. Based on the evaluation, ANVISA granted the GMP certification, confirming the facility’s compliance with Brazilian regulatory standards.
With this certificate, now both the API manufacturing sites of Wanbury continue to be compliant per ANVISA' s rules & regulations.
Wanbury is a pharmaceutical company with a presence in the global API market and domestic branded formulations.
The company's consolidated net profit declined 88.12% to Rs 1.22 crore as revenues fell by 8.28% to Rs 133.45 crore in Q3 FY25 as compared with Q3 FY24.
The counter declined 1.74% to Rs 299.35 on the BSE.
For the full year,net profit declined 45.44% to Rs 30.53 crore in the year ended March 2025 as against Rs 55.96 crore during the previous year ended March 2024. Sales rose 4.14% to Rs 599.51 crore in the year ended March 2025 as against Rs 575.65 crore during the previous year ended March 2024.
For the full year,net profit rose 0.43% to Rs 30.53 crore in the year ended March 2025 as against Rs 30.40 crore during the previous year ended March 2024. Sales rose 4.14% to Rs 599.51 crore in the year ended March 2025 as against Rs 575.65 crore during the previous year ended March 2024.